224 related articles for article (PubMed ID: 30546251)
1. Anakinra in Still's disease: a profile of its use.
Lyseng-Williamson KA
Drugs Ther Perspect; 2018; 34(12):543-553. PubMed ID: 30546251
[TBL] [Abstract][Full Text] [Related]
2. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
3. Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum.
Kontzias A; Petryna O; Nakasato P; Efthimiou P
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):45-57. PubMed ID: 38756937
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Hoffmann MC; Cavalli G; Fadle N; Cantoni E; Regitz E; Fleser O; Klemm P; Zaks M; Stöger E; Campochiaro C; Tomelleri A; Baldissera E; Bittenbring JT; Zimmer V; Pfeifer J; Fischer Y; Preuss KD; Bewarder M; Thurner B; Fuehner S; Foell D; Dagna L; Kessel C; Thurner L
J Clin Immunol; 2024 Jan; 44(2):45. PubMed ID: 38231276
[TBL] [Abstract][Full Text] [Related]
5. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
[TBL] [Abstract][Full Text] [Related]
6. Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings.
Hur P; Yi E; Ionescu-Ittu R; Manceur AM; Lomax KG; Cammarota J; Xie J; Gautam R; Nakasato P; Sanghera N; Kim N; Grom AA
Rheumatol Ther; 2022 Feb; 9(1):265-283. PubMed ID: 34874547
[TBL] [Abstract][Full Text] [Related]
7. Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.
Bindoli S; Baggio C; Doria A; Sfriso P
Drugs; 2024 Mar; 84(3):257-274. PubMed ID: 38441807
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Biological Drugs in Still's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Kilic B; Ozturk A; Karup S; Hacioglu E; Ugurlu S
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38775654
[TBL] [Abstract][Full Text] [Related]
9. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.
Segú-Vergés C; Coma M; Kessel C; Smeets S; Foell D; Aldea A
Arthritis Res Ther; 2021 Apr; 23(1):126. PubMed ID: 33892792
[TBL] [Abstract][Full Text] [Related]
10. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity.
Nirmala N; Brachat A; Feist E; Blank N; Specker C; Witt M; Zernicke J; Martini A; Junge G
Pediatr Rheumatol Online J; 2015 Nov; 13():50. PubMed ID: 26589963
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity.
Kudela H; Drynda S; Lux A; Horneff G; Kekow J
BMC Rheumatol; 2019; 3():4. PubMed ID: 30886992
[TBL] [Abstract][Full Text] [Related]
12. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes.
Vitale A; Cavalli G; Ruscitti P; Sota J; Colafrancesco S; Priori R; Valesini G; Argolini LM; Baldissera E; Bartoloni E; Cammelli D; Canestrari G; Cavallaro E; Massaro MG; Cipriani P; De Marchi G; De Vita S; Emmi G; Frassi M; Gerli R; Gremese E; Iannone F; Fornaro M; Paladini A; Lopalco G; Manna R; Mathieu A; Montecucco C; Mosca M; Piazza I; Piga M; Pontikaki I; Romano M; Rossi S; Rossini M; Silvestri E; Stagnaro C; Talarico R; Frediani B; Tincani A; Viapiana O; Vitiello G; Galozzi P; Sfriso P; Gaggiano C; Grosso S; Rigante D; Dagna L; Giacomelli R; Cantarini L
Front Med (Lausanne); 2020; 7():42. PubMed ID: 32154255
[No Abstract] [Full Text] [Related]
14. Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift?
Mitrovic S; Hassold N; Kamissoko A; Rosine N; Mathian A; Mercy G; Pertuiset E; Nocturne G; Fautrel B; Koné-Paut I
Rheumatology (Oxford); 2022 May; 61(6):2535-2547. PubMed ID: 34559214
[TBL] [Abstract][Full Text] [Related]
15. Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses.
Dunger-Baldauf C; Nakasato P; Noviello S; Whelan S; Bieth B
Rheumatol Ther; 2022 Apr; 9(2):753-762. PubMed ID: 35044647
[TBL] [Abstract][Full Text] [Related]
16. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
Nordström D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
J Rheumatol; 2012 Oct; 39(10):2008-11. PubMed ID: 22859346
[TBL] [Abstract][Full Text] [Related]
18. Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review).
Junge G; Mason J; Feist E
Semin Arthritis Rheum; 2017 Oct; 47(2):295-302. PubMed ID: 28757235
[TBL] [Abstract][Full Text] [Related]
19. Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry.
Vitale A; Caggiano V; Maggio MC; Lopalco G; Emmi G; Sota J; La Torre F; Ruscitti P; Bartoloni E; Conti G; Fabiani C; Mattioli I; Gaggiano C; Cardinale F; Dagna L; Campochiaro C; Giacomelli R; Balistreri A; Laskari K; Tufan A; Ragab G; Almaghlouth IA; Więsik-Szewczyk E; Pereira RM; Frediani B; Iannone F; Sfikakis PP; Cantarini L
Front Med (Lausanne); 2022; 9():1071732. PubMed ID: 36619631
[TBL] [Abstract][Full Text] [Related]
20. Anakinra for the treatment of adult-onset Still's disease.
Castañeda S; Atienza-Mateo B; Martín-Varillas JL; Serra López-Matencio JM; González-Gay MA
Expert Rev Clin Immunol; 2018 Dec; 14(12):979-992. PubMed ID: 30324816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
